A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis
Open Access
- 29 September 2021
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (4) , 2101612
Abstract
Background: Blood-derived biomarkers have been described extensively as potential prognostic markers in idiopathic pulmonary fibrosis (IPF), but studies have been limited by analyses using data-dependent thresholds, inconsistent adjustment for confounders and an array of end-points, thus often yielding ungeneralisable results. Meta-analysis of individual participant data (IPD) is a powerful tool to overcome these limitations. Through systematic review of blood-derived biomarkers, sufficient studies with measurements of matrix metalloproteinase (MMP)-7 were identified to facilitate standardised analyses of the prognostic potential of this biomarker in IPF.Methods: Electronic databases were searched on 12 November 2020 to identify prospective studies reporting outcomes in patients with untreated IPF, stratified according to at least one pre-specified biomarker, measured at either baseline, or change over 3 months. IPD were sought for studies investigating MMP-7 as a prognostic factor. The primary outcome was overall mortality according to standardised MMP-7 z-scores, with a secondary outcome of disease progression in 12 months, all adjusted for age, gender, smoking and baseline forced vital capacity.Results: IPD was available for nine studies out of 12 identified, reporting outcomes from 1664 participants. Baseline MMP-7 levels were associated with increased mortality risk (adjusted hazard ratio 1.23, 95% CI 1.03–1.48; I2=64.3%) and disease progression (adjusted OR 1.27, 95% CI 1.11–1.46; I2=5.9%). In limited studies, 3-month change in MMP-7 was not associated with outcomes.Conclusion: IPD meta-analysis demonstrated that greater baseline MMP-7 levels were independently associated with an increased risk of poor outcomes in patients with untreated IPF, while short-term changes did not reflect disease progression.Keywords
All Related Versions
Funding Information
- National Institute for Health Research (Funding: FK/IS are supported by the Nottingham Nat)
This publication has 44 references indexed in Scilit:
- Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case–control studyThorax, 2013
- Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for PracticePLOS ONE, 2012
- Individual participant data meta-analysis of prognostic factor studies: state of the art?BMC Medical Research Methodology, 2012
- Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- The rising incidence of idiopathic pulmonary fibrosis in the UKThorax, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The pathogenesis of idiopathic pulmonary fibrosisTherapeutic Advances in Respiratory Disease, 2010
- Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- To IPD or not to IPD?Evaluation & the Health Professions, 2002